Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Camrelizumab + Chemo in TNBC
NCT05438706Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fudan University. Primary endpoint: Overall Response Rate at 12 weeks. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05438706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438706.